In ZINC since | Heavy atoms | Benign functionality |
---|---|---|
October 5th, 2005 | 28 | No |
Popular Name: Dexamethasone Dexamethasone
(11beta,16alpha)-9-Fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione
.delta.(sup 1)-9-.alpha.-Fluoro-16-.alpha.-methylcortisol
1-Dehydro-16.alpha.-methyl-9.alpha.-fluorohydrocortisone
1-Dehydro-16alpha-methyl-9alpha-fluorohydrocortisone
16-alpha-Methyl-9-alpha-fluoro-1-dehydrocortisol
16-alpha-Methyl-9-alpha-fluoro-delta(sup 1)-hydrocortisone
16-alpha-Methyl-9-alpha-fluoro-delta1-hydrocortisone
16-alpha-Methyl-9-alpha-fluoroprednisolone
16.alpha.-Methyl-9.alpha.-fluoro-1-dehydrocortisol
16.alpha.-Methyl-9.alpha.-fluoroprednisolone
16alpha-Methyl-9alpha-fluoro-1-dehydrocortisol
16alpha-Methyl-9alpha-fluoro-delta(sup 1)-hydrocortisone
16alpha-Methyl-9alpha-fluoroprednisolone
50-02-2; C15643; Dexamethasone
50-02-2; CPD001227192; Dexamethasone; SAM002548948
50-02-2; D00292; Decadron (TN); Dexamethasone (JP16/USP/INN); Maxidex (TN)
9-alpha-Fluoro-16-alpha-methylprednisolone
9.alpha.-Fluoro-16.alpha.-methylprednisolone
9A-FLUORO-16BETA-METHYLPREDNISOLONE
9alpha-Fluoro-16alpha-methyl-11beta,17alpha,21-trihydroxy-1,4-pregnadiene-3,20-dione
9alpha-Fluoro-16alpha-methylprednisolone
CPD001227192; Dexamethasone; SAM002548948
delta(sup 1)-9-alpha-Fluoro-16-alpha-methylcortisol
delta1-9alpha-Fluoro-16alpha-methylcortisol
dexametasona; dexamethasone; dexamethasonum
Dexamethasone Sodium Phosphate
Prednisolone, 9.alpha.-fluoro-16.alpha.-methyl-
Prednisolone, 9alpha-fluoro-16alpha-methyl-
pregna-1,4-diene-3,20-dione, 9-fluoro-11,17,21-trihydroxy-16-methyl-, (11b,16a)-
Type pH range | xlogP | Des A‑Pol Apolar desolvation (kcal/mol) | Des Pol Polar desolvation (kcal/mol) | H Don H-bond donors | H Acc H-bond acceptors | Chg Net charge | tPSA (Ų) | MWT Molecular weight (g/mol) | RB Rotatable bonds | DL |
---|---|---|---|---|---|---|---|---|---|---|
Ref Reference (pH 7) | 2.06 | 3.98 | -16.38 | 3 | 5 | 0 | 95 | 392.467 | 2 | ↓ |
Note Type | Comments | Provided By |
---|---|---|
Molecular_Solubility | 3.784 | Bitter DB |
MP | 253 - 255 | Enamine Building Blocks |
MP | 253...255 | Enamine Building Blocks |
Mp [°C] | 255 - 261 | Acros Organics |
ALOGPS_SOLUBILITY | 5.05e-02 g/l | DrugBank-approved |
purity | 9.500000000000000e+001 | Enamine Building Blocks Enamine Building Blocks |
Purity | 97% | APIChem |
Melting_Point | ca 260? dec. | Alfa-Aesar |
Melting_Point | ca 260° dec. | Alfa-Aesar |
UniProt Database Links | CATE_RAT; CDA7L_HUMAN; CDA7L_MOUSE; CDA7L_RAT; CEA19_HUMAN; CHID1_HUMAN; COT2_BOVIN; COT2_CHICK; COT2_HUMAN; COT2_MOUSE; COT2_RAT; CP2A6_HUMAN; CP3A2_RAT; CP3AB_MOUSE; CP3AI_RAT; CP3AV_MESAU; DCSTP_HUMAN; DDIT4_MOUSE; DDIT4_RAT; DEXI_DANRE; DEXI_HUMAN; DE | ChEBI |
Patent Database Links | EP0769300; EP0806140; EP0970694; EP1110552; EP1176140; EP1310488; EP1382339; EP1438962; EP1527772; EP1543839; EP1559778; EP1584682; EP1588702; EP1611877; EP1611879; EP1616569; EP1621219; EP1625854; EP1629833; EP1637126; EP1637156; EP1637164; EP1659172; EP | ChEBI |
Therapy | glucocorticoid | SMDC Pharmakon |
H phrase | H351: Suspected of causing cancer | Acros Organics |
Target | IL Receptor | Selleck Chemicals |
PUBCHEM_SUBSTANCE_COMMENT | NCC_SAMPLE_SUPPLIER : Enamine; NCC_SUPPLIER_STRUCTURE_ID : 207696704 | NIH Clinical Collection via PubChem |
Therapy | Nuclear receptor ligands: corticosteroid | SMDC Iconix |
P phrase | P281: Use personal protective equipment as required | Acros Organics |
R phrase | R40: Limited evidence of a carcinogenic effect. | Acros Organics |
S phrase | S45: In case of accident or if you feel unwell, seek medical advice immediately (show the label where possible). | Acros Organics |
PUBCHEM_SUBSTANCE_COMMENT | SAMPLE_SUPPLIER: Enamine; SUPPLIER_STRUCTURE_ID: 207696704 | NIH Clinical Collection via PubChem |
Hazard | XN: Harmful | Acros Organics |
Code | Description | Organism Class | Affinity (nM) | LE (kcal/mol/atom) | Type |
---|---|---|---|---|---|
ANDR-2-E | Androgen Receptor (cluster #2 Of 4), Eukaryotic | Eukaryotes | 1000 | 0.30 | Binding ≤ 10μM |
GCR-2-E | Glucocorticoid Receptor (cluster #2 Of 2), Eukaryotic | Eukaryotes | 22 | 0.38 | Binding ≤ 10μM |
MCR-1-E | Mineralocorticoid Receptor (cluster #1 Of 2), Eukaryotic | Eukaryotes | 7 | 0.41 | Binding ≤ 10μM |
PRGR-1-E | Progesterone Receptor (cluster #1 Of 3), Eukaryotic | Eukaryotes | 1000 | 0.30 | Binding ≤ 10μM |
GCR-2-E | Glucocorticoid Receptor (cluster #2 Of 2), Eukaryotic | Eukaryotes | 4 | 0.42 | Functional ≤ 10μM |
Z50594-7-O | Mus Musculus (cluster #7 Of 9), Other | Other | 5 | 0.42 | Functional ≤ 10μM |
Z50597-11-O | Rattus Norvegicus (cluster #11 Of 12), Other | Other | 20 | 0.38 | Functional ≤ 10μM |
Z80178-2-O | J774.A1 (Macrophage Cells) (cluster #2 Of 3), Other | Other | 48 | 0.37 | Functional ≤ 10μM |
Z80301-2-O | N9 (cluster #2 Of 2), Other | Other | 74 | 0.36 | Functional ≤ 10μM |
Z80418-3-O | RAW264.7 (Monocytic-macrophage Leukemia Cells) (cluster #3 Of 9), Other | Other | 860 | 0.30 | Functional ≤ 10μM |
Z80548-4-O | THP-1 (Acute Monocytic Leukemia Cells) (cluster #4 Of 5), Other | Other | 7 | 0.41 | Functional ≤ 10μM |
Z80954-3-O | HFF (Foreskin Fibroblasts) (cluster #3 Of 4), Other | Other | 2 | 0.43 | Functional ≤ 10μM |
Z81247-4-O | HeLa (Cervical Adenocarcinoma Cells) (cluster #4 Of 9), Other | Other | 17 | 0.39 | Functional ≤ 10μM |
Z81338-2-O | T-cells (cluster #2 Of 3), Other | Other | 5 | 0.42 | Functional ≤ 10μM |
Uniprot | Swissprot | Description | Affinity (nM) | LE (kcal/mol/atom) | Type |
---|---|---|---|---|---|
ANDR_HUMAN | P10275 | Androgen Receptor, Human | 1000 | 0.30 | Binding ≤ 1μM |
GCR_RAT | P06536 | Glucocorticoid Receptor, Rat | 22 | 0.38 | Binding ≤ 1μM |
GCR_HUMAN | P04150 | Glucocorticoid Receptor, Human | 0.51 | 0.46 | Binding ≤ 1μM |
MCR_HUMAN | P08235 | Mineralocorticoid Receptor, Human | 1000 | 0.30 | Binding ≤ 1μM |
PRGR_HUMAN | P06401 | Progesterone Receptor, Human | 1000 | 0.30 | Binding ≤ 1μM |
ANDR_HUMAN | P10275 | Androgen Receptor, Human | 1000 | 0.30 | Binding ≤ 10μM |
GCR_RAT | P06536 | Glucocorticoid Receptor, Rat | 22 | 0.38 | Binding ≤ 10μM |
GCR_HUMAN | P04150 | Glucocorticoid Receptor, Human | 0.51 | 0.46 | Binding ≤ 10μM |
MCR_HUMAN | P08235 | Mineralocorticoid Receptor, Human | 1000 | 0.30 | Binding ≤ 10μM |
PRGR_HUMAN | P06401 | Progesterone Receptor, Human | 1000 | 0.30 | Binding ≤ 10μM |
GCR_HUMAN | P04150 | Glucocorticoid Receptor, Human | 0.2 | 0.48 | Functional ≤ 10μM |
Z81247 | Z81247 | HeLa (Cervical Adenocarcinoma Cells) | 17 | 0.39 | Functional ≤ 10μM |
Z80954 | Z80954 | HFF (Foreskin Fibroblasts) | 0.5 | 0.47 | Functional ≤ 10μM |
Z80178 | Z80178 | J774.A1 (Macrophage Cells) | 48 | 0.37 | Functional ≤ 10μM |
Z50594 | Z50594 | Mus Musculus | 0.1 | 0.50 | Functional ≤ 10μM |
Z80301 | Z80301 | N9 | 74 | 0.36 | Functional ≤ 10μM |
Z50597 | Z50597 | Rattus Norvegicus | 20 | 0.38 | Functional ≤ 10μM |
Z80418 | Z80418 | RAW264.7 (Monocytic-macrophage Leukemia Cells) | 10 | 0.40 | Functional ≤ 10μM |
Z81338 | Z81338 | T-cells | 5 | 0.42 | Functional ≤ 10μM |
Z80548 | Z80548 | THP-1 (Acute Monocytic Leukemia Cells) | 50 | 0.37 | Functional ≤ 10μM |
Description | Species |
---|---|
BMAL1:CLOCK,NPAS2 activates circadian gene expression | |
Circadian Clock |
Description | Species |
---|---|
BMAL1:CLOCK,NPAS2 activates circadian gene expression | |
Nuclear Receptor transcription pathway | |
Nuclear signaling by ERBB4 |